A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells

Urologia Internationalis

Volumn 77, Issue 4, 2006, Pages 347-354

  Hasegawa, Nobuko ^a   Mizutani, Kosuke ^b   Suzuki, Tohru ^b   Deguchi, Takashi ^b   Nozawa, Yoshinori ^a  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Camptothecin drug resistance; Prostate cancer; Protein profiling; Proteomics

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; GALECTIN 3; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE TRANSFERASE M1; LIPOCORTIN 1; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MALE; MASS SPECTROMETRY; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33750948495     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096340     Document Type: Article

References (25)

1. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF, Emmert-Buck MR: Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9-15.
2. Paweletz CP, Liotta LA, Petricoin EF III: New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 2001;57:160-163.
3. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR: Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000;21:2235-2242.
4. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
5. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF: Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003;3:2142-2146.
6. Utleg AG, Yi EC, Xie T, Shannon P, White JT, Goodlette DR, Hood L, Lin B: Proteomic analysis of human prostasomes. Prostate 2003;56:150-161.
7. Waghray A, Feroze F, Schober MS, Yao F, Wood C, Puravs E, Krause M, Hanash S, Chen YQ: Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 2001;1:1327-1338.
8. Li J, LeRiche T, Tremblay TL, Wang C, Bonneil E, Harrison DJ, Thibault P: Application of microfluidic devices to proteomics research. Mol Cell Proteomics 2002;1:157-168.
9. Meehan KL, Sadar MD: Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 2004;4:1116-1134.
10. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS: Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004;64:347-355.
11. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF III: Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003;3:1801-1810.
12. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN: Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002;81:191-201.
13. Zhivotovsky B, Orrenius S: Defects in the apoptotic machinery of cancer cells: role in drug resistance. Semin Cancer Biol 2003;13:125-134.
14. Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ: Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999;59:5842-5848.
15. Akao Y, Kusakabe S, Banno Y, Kito M, Nakazawa Y, Tamiya-Koizumi KT, Hattori M, Sawada M, Hirabayashi Y, Ohishi N, Nozawa Y: Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells. Biochem Biophys Res Commun 2002;294:363-370.
16. Rasheed ZA, Rubin EH: Mechanisms of resistance to topoisomerase I targeting drugs. Oncogene 2003;22:7296-7304.
17. Catz SD, Johnson JL: BCL-2 in prostate cancer. Apoptosis 2003;8:29-37.
18. Arha IN, Song K, Seth P, Cowen KH, Sinha BK: Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res 1998;18:1845-1850.
19. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-3567.
20. Pappin DJ, Hojrup P, Bleasby AJ: Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 1993;3:327-332.
21. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE: Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate 2003;56:98-105.
22. Gieffers C, Korioth F, Heimann P, Ungermann C, Frey J: Mitofilin is a transmembrane protein of the inner mitochondrial membrane expressed as two isoforms. Exp Cell Res 1997;232:395-399.
23. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E: Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 2004;314:565-570.
24. Califice S, Castronovo, Bracke M, van den Brûle F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004;23:7527-7536.
25. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS: Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors. J Biol Chem 2003;278:20915-20924.